Mirvetuximab soravtansine shows durable efficacy in ovarian cancer subset

Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers, according to a results of the phase 3 SORAYA study.
The findings, presented during Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer, showed mirvetuximab soravtansine (IMGN853, ImmunoGen), an antibody-drug conjugate, induced clinically meaningful and durable antitumor activity with acceptable tolerability among the subgroup of women, who have limited treatment options.
“In the

Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers, according to a results of the phase 3 SORAYA study.
The findings, presented during Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer, showed mirvetuximab soravtansine (IMGN853, ImmunoGen), an antibody-drug conjugate, induced clinically meaningful and durable antitumor activity with acceptable tolerability among the subgroup of women, who have limited treatment options.
“In the